Testing azacitidine plus venetoclax for acute myeloid leukemia
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This early-phase trial tests whether azacitidine (CC-486) plus venetoclax can help people with acute myeloid leukemia (AML) that is not APL. It’s designed to find safe dosing and see how well the combination works for newly diagnosed or relapsed/refractory AML.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have AML that is not APL, confirmed by your leukemia test results
- You’ve either had at least one prior treatment, or you’re newly diagnosed; hydroxyurea or ATRA may have been used for newly diagnosed cases
- Your doctor thinks you may not tolerate “intensive” chemotherapy because of age or other health problems
- Your health status is limited but not too low: you must score 0 to 3 on the ECOG scale (or 0 to 2 if age 75+)
- Kidney and liver tests must be adequate enough for study treatment (and you must have at least 12 weeks estimated life expectancy)
- You cannot have certain problems like AML in the brain (CNS), uncontrolled infections, or severe medication absorption issues
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs, venetoclax and a hypomethylating agent (HMA), as the first treatment for adults with a type of leukemia called AML. The goal is to see if this combination works well and is safe for patients who have not had prior chemotherapy.
This trial tests a combination of three oral medications (chidamide, venetoclax, and azacitidine) for people newly diagnosed with acute myeloid leukemia (AML) who cannot receive strong chemotherapy. The goal is to see if this gentler treatment can work well with fewer side effects.
This trial tests a combination of oral venetoclax and injected azacitidine for adults who are newly diagnosed with acute myeloid leukemia (AML) and cannot have standard strong chemotherapy. The goal is to see how well this treatment works and what side effects it may cause.
This Phase 2 study tests whether the combination of azacitidine and venetoclax can help people with acute myeloid leukemia (AML) who can’t handle standard intensive chemotherapy, including some relapsed or refractory cases. It also involves extra optional-style lab testing on your leukemia (bio-banking and “-omics” profiling) to learn which drug sensitivities may matter.
This Phase 1 trial tests a combination of azacitidine, venetoclax, and donor NK cells to treat acute myeloid leukemia (AML) or certain AML-like syndromes. It’s designed mainly to find safe dosing and whether this approach can control the leukemia.
This trial studies whether adding venetoclax to either azacitidine or decitabine can treat acute myeloid leukemia (AML) when earlier “hypomethylating” treatment has stopped working. You might be a candidate if you’ve already tried azacitidine or decitabine for a related blood condition and it failed, and you meet the health-safety limits.
Hear when a new AML trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.